In patients with advanced HCC, nivolumab, an anti-PD-1 agent, produced an objective response rate (ORR) of 20% in the dose expansion phase of a phase 1/2 clinical trial treating 214 patients with 3 mg/kg nivolumab. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.